TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04416594

Intervention type: OTHER
Intervention: Data collection
Description: Only data collection
Study: NCT04294576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BJ-001
Description: BJ-001 dosed via SC injection as single agent. One cycle is 6 weeks.
Study: NCT02308553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib (150 mg or 200 mg BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nintedanib-Placebo
Description: Placebo (150 mg or 200 mg BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel as 90mg/mw infusion day 1, 8, 15 q28 (6 cycles)
Study: NCT01074359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A0001 (alpha-tocopherolquinone)
Description: 28 days (1.5 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
Study: NCT01713647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipin, losartan, HCTZ
Study: NCT01074359

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 28 days of placebo oral capsules. Treatment taken twice daily with meals.
Study: NCT02308553

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel as 90mg/mw infusion day 1, 8, 15 q28 (6 cycles)
Study: NCT03185325

Intervention type: OTHER
Intervention: bone marrow puncture and venous blood samples
Description: bone marrow and peripheral blood samples are collected in non hodgkin lymphoma patients

Intervention type: OTHER
Intervention: venous blood samples
Description: venous blood samples are collected in healthy voulnteers
Study: NCT01713647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipin, losartan, HCTZ
Study: NCT02181491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]-P943
Study: NCT02023580

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video treatments
Description: The treatment video vignettes to be delivered between Baseline and 3 Months include: 1) Condom use/anal sex without HIV status disclosure (potentially SDCAS); 2) Condom use/anal sex without HIV status disclosure and perceived responsibility; 3) Discussion of nondisclosure of HIV status prior to sex and perceived responsibility, STIs; 4) Stigma associated with disclosing HIV status to sex partners; 5) HIV/STI testing; and 6) Diagnosis of an STI; STI disclosure to sex partners and perceived responsibility.~Video boosters to be delivered weekly for 4 weeks between 6 and 9 Months include: 7) HIV status disclosure, condom use, STIs; 8) STI disclosure to sex partners, disclosure to friends, serodiscordant partnerships; 9 \& 10) Support of HIV disclosure and perceived responsibility.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video treatments
Description: The treatment video vignettes to be delivered between Baseline and 3 Months include: 1) Condom use/anal sex without HIV status disclosure (potentially SDCAS); 2) Condom use/anal sex without HIV status disclosure and perceived responsibility; 3) Discussion of nondisclosure of HIV status prior to sex and perceived responsibility, STIs; 4) Stigma associated with disclosing HIV status to sex partners; 5) HIV/STI testing; and 6) Diagnosis of an STI; STI disclosure to sex partners and perceived responsibility.~Video boosters to be delivered weekly for 4 weeks between 6 and 9 Months include: 7) HIV status disclosure, condom use, STIs; 8) STI disclosure to sex partners, disclosure to friends, serodiscordant partnerships; 9 \& 10) Support of HIV disclosure and perceived responsibility.
Study: NCT01734785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin + Linagliptin
Description: Fixed dose combination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin + Linagliptin
Description: Fixed dose combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin + Linagliptin
Description: Fixed dose combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin placebo + Linagliptin placebo
Description: Matching Empagliflozin + Linagliptin low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin + Linagliptin
Description: Fixed dose combination.
Study: NCT03935789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BLAST
Description: 12-week self-guided intervention using a web-based platform
Study: NCT02152475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mouthwash with curcumin
Description: Mouthwash with 20 ml of curcumin solution for 5 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mouthwash with curcumin
Description: Mouthwash with 20 ml of curcumin solution for 5 minutes
Study: NCT04294576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BJ-001
Description: BJ-001 dosed via SC injection as single agent. One cycle is 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: BJ-001 dosed via SC injection in combination with Pembrolizumab~One cycle is 6 weeks.
Study: NCT02807532

Intervention type: OTHER
Intervention: atrial fibrillation
Description: In the case-control trial, patients with atrial fibrillation 7 days after surgery will be assigned to an atrial fibrillation group.

Intervention type: OTHER
Intervention: non-atrial fibrillation
Description: In the case-control trial, patients without atrial fibrillation 7 days after surgery will be assigned to a non-atrial fibrillation group.
Study: NCT02455232

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: upper limb muscle block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4cc of lidocaïne®
Study: NCT00825591

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Oral administration before bed. We will test two doses (0.5 or 3.0 mg/m2. 6 week duration.)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Oral administration before bed. 6 week duration.
Study: NCT03766581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Oral administration
Study: NCT03766191

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food Ads
Description: Exposure to foods ads embedded in an age-appropriate TV program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food Ads
Description: Exposure to foods ads embedded in an age-appropriate TV program

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non-food Ads
Description: Exposure to non-food ads embedded in an age-appropriate TV program

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non-food Ads
Description: Exposure to non-food ads embedded in an age-appropriate TV program
Study: NCT04069416

Intervention type: PROCEDURE
Intervention: living donor liver transplantation
Description: liver graft from a living donor

Intervention type: PROCEDURE
Intervention: living donor liver transplantation
Description: liver graft from a living donor

Intervention type: PROCEDURE
Intervention: living donor liver transplantation
Description: liver graft from a living donor
Study: NCT02844439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesevatinib
Study: NCT03450460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support
Description: The Program matches volunteer Mentors and Partners for a series of one-to-one interactions that focus on the discussion and resolution of problems or issues (i.e., problem solving) related to one or several key topic areas including family and friends, resources, life changes or challenges, (health care) professionals, social/recreational activities, work/employment/training/volunteering, the brain injury itself, emotions or feelings, and other issues.27 Once the match is established, the Mentor and Partner communicate with one another primarily by telephone until the problems or issues are either resolved or a referral to another service is made (i.e., counselling or community support services). For some partnerships, communication by email or video conferencing is used.27 Most telephone calls last between 20 and 40 minutes (personal communication) and are held weekly.
Study: NCT01638000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin succinate
Description: oral tablet
Study: NCT01315340

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ocular rigidity, outflow facility and intraocular pressure measurement
Description: The measurement procedure includes cannulation of the anterior chamber of the eye, under sterile conditions. Infusion of the eye with microvolumes of a saline solution is performed, followed by manometric measurement of intraocular pressure, in order to quantify ocular rigidity. Outflow facility is estimated from recordings of intraocular pressure after the infusion is stopped.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ocular rigidity, outflow facility and intraocular pressure measurement
Description: The measurement procedure includes cannulation of the anterior chamber of the eye, under sterile conditions. Infusion of the eye with microvolumes of a saline solution is performed, followed by manometric measurement of intraocular pressure, in order to quantify ocular rigidity. Outflow facility is estimated from recordings of intraocular pressure after the infusion is stopped.
Study: NCT00939094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2066
Description: Capsule, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, once daily
Study: NCT01758640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Low dose warfarin of 5mg or less per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Low dose warfarin of 5mg or less per day
Study: NCT02152475

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: blue LED illumination
Description: Oral cavity was illuminated with blue light for 5 minutes
Study: NCT03766581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Oral administration
Study: NCT02152475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blue LED illumination
Description: Oral cavity was illuminated with blue light for 5 minutes
Study: NCT03766581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: Oral administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Administration
Study: NCT01162954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-6034

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02468531

Intervention type: OTHER
Group type: OTHER
Intervention: oxygen
Description: 50% oxygen inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: 50% Xenon inhalation
Study: NCT03766581

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Oral administration
Study: NCT00239993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glatiramer acetate
Study: NCT03766581

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Oral administration
Study: NCT00239993

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Warm compress prior to injection of glatiramer acetate
Study: NCT01308814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Transdermal 17β-estradiol (100 ug/day) for 12 months, administered as patches to be worn continuously and replaced once a week. Also, every 2 months, oral micronized progesterone (200 mg/day x 12 days) will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patches for 12 months, to be worn continuously and replaced once a week. Also, placebo pills will be administered for 12 days every 2 months.
Study: NCT01827436

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asymmetrical gait training
Study: NCT01193634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR 9250 / DR 9550 / CRT 9750
Description: Active implantable defibrillators range
Study: NCT01230996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Each patient will also receive chemotherapy with a drug called cisplatin, which is given intravenously through a drip in the arm once a week during their 6 week radiotherapy treatment. Again this is standard treatment for any patient with cervix cancer.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy
Description: Patients in this trial will receive radiotherapy to the pelvic area with additional chemotherapy (chemoradiotherapy). This is the standard treatment for cervix cancer and will be almost identical to patients not taking part in this study. As patients in the study will be treated with IMRT, the total radiation dose will be slightly higher but without increasing the dose to normal tissue in the pelvis. This will mean the number of radiotherapy treatments that each patient receives in the study is between 27 and 30 compared with the usual 28. Each patient will undergo 6 weeks of radiotherapy treatment and must attend the radiotherapy department hospital once daily (Monday to Friday) over 6 weeks. Each treatment lasts for approximately 10 15 minutes. This is exactly the same as standard practice if patients were not participating in the trial.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracavitary brachytherapy
Description: Intracavitary brachytherapy Intracavitary brachytherapy will be given towards the end of external beam radiotherapy usually weeks five and six. This is routine treatment and will be given according to local practice As is the convention patients will be reviewed weekly (more frequently if necessary) by their study doctor and will have weekly blood tests to measure full blood count and urea and electrolytes.
Study: NCT02876237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: geriatric assessment and quality of life
Description: Included patient must have a geriatric assessment before radiotherapy and 6 months later. This standardized geriatric assessment will collect social information, functional, sensory, cognitive, emotional, motor, nutritional, and medical related to comorbidities .~Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: standard radiotherapy
Study: NCT02058316

Intervention type: DEVICE
Intervention: Lateral Flow Device Test
Description: Testing of leftover BAL samples from clinical routine by the lateral flow device test
Study: NCT02483923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrasound guided serratus anterior block with ropivacaine
Description: After induction of anesthesia, patients take ultrasound guided serratus anterior plane block with 0.5ml/kg of ropivacaine 0.375%. 30minutes before the end of operation, intravenous patient controlled analgesia (Basal rate 0ml/hr, 0.5mcg/kg of fentanyl, lock-out time 10minutes) is connected to patient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intravenous PCA only
Description: same dose of intravenous patient controlled analgesia (Basal rate 0ml/hr, 0.5mcg/kg of fentanyl, lock-out time 10minutes) is connected to patient only.
Study: NCT02572505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Female patient will take Truvada and use condoms for each act of intercourse except once at the optimal time for fertility.
Study: NCT02882061

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic spinal manipulation
Description: The most hypomobile (stiff) and/or painful segment between T1-T4 will be determined , and this is the segment to which the examiner will apply the thrust. The manipulation will be performed with subjects lying supine. The examiner will use a 'pistol grip' to apply pressure on the articular pillars of the thoracic segment bilaterally in order to block the inferior vertebrae of the hypomobile segment. The subject will cross their arms over their chest to the point where the elbows are aligned. This will allow the examiner to apply pressure through both elbows in an anterior-to-posterior direction. The examiner will assure the direction of force is felt into his/her stabilizing hand. The subject will be asked to take a deep breath in and then exhale completely. A grade V (HVLA) thrust will be applied at the end of the subject's exhalation. If a cavitation is not heard or felt by either the subject or examiner, a second thrust will be performed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic spinal manipulation
Description: The most hypomobile (stiff) and/or painful segment between T1-T4 will be determined , and this is the segment to which the examiner will apply the thrust. The manipulation will be performed with subjects lying supine. The examiner will use a 'pistol grip' to apply pressure on the articular pillars of the thoracic segment bilaterally in order to block the inferior vertebrae of the hypomobile segment. The subject will cross their arms over their chest to the point where the elbows are aligned. This will allow the examiner to apply pressure through both elbows in an anterior-to-posterior direction. The examiner will assure the direction of force is felt into his/her stabilizing hand. The subject will be asked to take a deep breath in and then exhale completely. A grade V (HVLA) thrust will be applied at the end of the subject's exhalation. If a cavitation is not heard or felt by either the subject or examiner, a second thrust will be performed.
Study: NCT00669825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALV003
Description: Doses via intragastric tube at dosages of either 100 mg, 300 mg, 900 mg, or 1800 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be administered via intragastric tube
Study: NCT00606541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Description: This is an investigator-initiated, single site study, consisting of two phases: 1) 8-week, open label treatment with quetiapine XR (50-400 mg/day) in subjects (n=55 in order to randomize 20 into each of the quetiapine XR and PBO arms in the 2nd phase of the study) with SAD; and 2) in those who demonstrate at least minimal improvement (i.e. CGI≤3), 12-weeks randomized, double-blind treatment with either quetiapine XR or placebo (PBO).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02426567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exclusive Enteral Nutrition (EEN)
Description: One week course of an isocaloric exclusive milk-based diet
Study: NCT01758640

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenindione
Description: Phenindione of 100mg or less per day
Study: NCT02426567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exclusive Enteral Nutrition (EEN)
Description: One week course of an isocaloric exclusive milk-based diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)
Description: One week course of an isocaloric, exclusion food-based diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)
Description: One week course of an isocaloric, exclusion food-based diet
Study: NCT04717544

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Arm
Description: The smoking cessation intervention will include 1) a six-week, 60-75 minute weekly cognitive-behavioral therapy (CBT) smoking cessation counseling group; and 2) smoking cessation medication include varenicline (Chantix), bupropion (Zyban) and nicotine replacement therapy (NRT). Dispensing these medications will include a 15-minute medication management visit with a prescribing clinician. Clients will choose their own preferred treatment. The standard prescription for NRT will include a transdermal patch at a dose that approximates for current average mg of nicotine intake and nicotine gums or lozenges (in either 2 mg or 4 mg strengths). Prescription for varenicline will be 0.5 mg once daily for three days, then 0.5 mg twice daily for the next four days, then 1 mg twice daily thereafter. Absent any contraindications to the drugs listed above, bupropion (Zyban) 150mg will be offered and prescribed once daily for one week, following by bupropion 300 mg once daily thereafter.
Study: NCT01685242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-170 0.24%
Description: 1 drop in each eye at 2 separate times during a 14 day period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AC-170 0%
Description: 1 drop in each eye at 2 separate times during a 14 day period
Study: NCT01391169

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: seromuscular flap enforcement
Description: seromuscular flap enforcement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: seromuscular flap enforcement
Description: seromuscular flap enforcement
Study: NCT04060069

Intervention type: OTHER
Intervention: Ringer Lactate
Description: Fluids